N4P
NEUTRALN4 Pharma Provides Operational Update on Nuvec® Platform
The biotech company provides an update on the progress of its Nuvec® gene delivery system, including collaborations, preclinical studies, and intellectual property developments.
N4 Pharma
0.5250GBX
0.00%
Market Cap
4.37M
Volume
127.29k
5% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.44
Day Range
0.5000p - 0.5500p
52 Week Range
0.3500p0.5250p1.0000p
0.5250p
Upcoming Events
N4P
NEUTRALN4 Pharma Reports Progress in Nuvec® Platform Development and Improved Cash Position
The biotech firm reported reduced operating losses and an improved cash position following a successful placing. Progress in its Nuvec® platform development and new collaborations were highlighted, though it remains pre-revenue.
N4P
NEUTRALN4 Pharma Announces Partnership with University of Strathclyde's CMAC
The biotech company has announced a collaboration with the University of Strathclyde's CMAC facility to advance the development of its Nuvec gene delivery platform.
N4P
NEUTRALN4 Pharma Announces Successful Targeted Delivery of RNA to Lung Cancer Cells Using Nuvec®
The biotech company reports successful targeted delivery of RNA to lung cancer cells using its Nuvec® platform, strengthening the potential of its gene delivery system.
N4P
NEUTRALN4 Pharma Announces Interim Results Presentation
The biotech company will announce its interim results and hold an investor presentation later this month.
N4P
NEUTRALN4 Pharma to Present at ShareSoc Growth Company Seminar
The biotech company will present on its Nuvec® gene delivery system at an upcoming investor event.
N4P
NEUTRALN4 Pharma Shares New Article on Nuvec®'s Potential in RNA Therapeutics
The biotech company has published a new article highlighting the potential of its Nuvec® gene delivery system for RNA therapeutics.
N4P
NEUTRALN4 Pharma Announces Investor Webinar
The biotech company is hosting an investor webinar to provide a strategic update on the development of its Nuvec® gene delivery system.
N4P
NEUTRALN4 Pharma Appoints New Non-Executive Director
The biotech company has appointed a new non-executive director to its board, representing its largest shareholder.
N4P
NEUTRALN4 Pharma Provides AGM Update on Nuvec® Platform Progress
The biotech company updates on the development of its Nuvec® gene delivery system, highlighting upcoming work to strengthen the commercial data package.